Form 4: ADMA Biologics Director Alison Finger Reports Stock and Option Grants
SEC Form 4
Alison Finger, a director at ADMA Biologics, reported the acquisition of restricted stock units and stock options on February 26, 2024.
Summary
- Alison Finger, a director of ADMA Biologics, filed a Form 4 detailing changes in beneficial ownership.
- On February 26, 2024, Ms. Finger acquired 24,040 restricted stock units (RSUs).
- These RSUs vest in two equal installments over a year.
- Ms. Finger also acquired options to purchase 37,541 shares of common stock at an exercise price of $5.40.
- These options vest in 12 equal monthly installments over a year and expire on February 26, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
- The vesting schedules encourage continued service and commitment to the company.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of transaction: grant of RSUs and stock options |
| 02/28/2024 | Date of Form 4 filing |
| 02/26/2034 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.